New data presented American Society of Hematology (ASH) Annual Meeting and Exposition supports the use of iptacopan over standard of care therapy for patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH). A team, led by Regis Peffault De Latour, French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, reported the primary efficacy and safety data from a 24-week, randomized treatment period of the pivotal, multicenter, phase 3 APPLY-PNH trial. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more